[ 1 ] Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009;69(14):1879–901. link1

[ 2 ] Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69(9):2305–9. link1

[ 3 ] Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 2017;72 (1):29–39. link1

[ 4 ] Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 2017;8(4):403–16. link1

[ 5 ] Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime–avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2017;61(8):e00883-17. link1

[ 6 ] Van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Antibacterial Resistance Leadership Group. Colistin versus ceftazidime–avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018;66(2):163–71. link1

[ 7 ] Coskun Y, Atici S. Successful treatment of pandrug-resistant Klebsiella pneumoniae infection with ceftazidime–avibactam in a preterm infant: a case report. Pediatr Infect Dis J 2020;39(9):854–6. link1

[ 8 ] Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-b-lactam blactamase inhibitors. Curr Opin Microbiol 2011;14(5):550–5. link1

[ 9 ] Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum blactamases, and porin mutations on the in vitro activity of ceftazidime– avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 2015;59(9):5793–7. link1

[10] Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, et al. First report of ceftazidime–avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 2015;59 (10):6605–7. link1

[11] Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime–avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2017;61(3):e02097–16. link1

[12] Hemarajata P, Humphries RM. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother 2019;74(5):1241–3. link1

[13] Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, McConville TH, et al. Successive emergence of ceftazidime–avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother 2018;62(3):e02101–e2117. link1

[14] Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients. Int J Antimicrob Agents 2019;53(6):774–80. link1

[15] Drawz SM, Papp-Wallace KM, Bonomo RA. New b-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 2014;58(4):1835–46. link1

[16] Ehmann DE, Jahic´ H, Ross PL, Gu RF, Hu J, Kern G, et al. Avibactam is a covalent, reversible, non-b-lactam b-lactamase inhibitor. Proc Natl Acad Sci USA 2012;109(29):11663–8. link1

[17] Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 2013;68(10):2286–90. link1

[18] Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovshi R, Griffith DC, et al. Vaborbactam: spectrum of b-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017;61(11):e01443–17. link1

[19] Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. Discovery of a cyclic boronic acid b-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 2015;58(9):3682–92. link1

[20] Gomez-Simmonds A, Stump S, Giddins MJ, Annavajhala MK, Uhlemann AC. Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem–relebactam in diverse Enterobacteriaceae. Antimicrob Agents Chemother 2018;62(8):e00573–18. link1

[21] Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55(1):390–4. link1

[22] Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, et al. Kinetics of avibactam inhibition against Class A, C, and D b-lactamases. J Biol Chem 2013;288(39):27960–71. link1

[23] Allergan. Summary of product characteristics, food and drug administration, ceftazidime avibactam (AvycazTM) [Internet]. Dublin: Allergan; 2019 [cited 2020 Dec 5]. Available from: https://www.allergan.com/assets/pdf/avycaz_pi. link1

[24] AstraZeneca. Summary of product characteristics: European medicines agency SPC for ceftazidime avibactam (ZaviceftaTM) [Internet]. London: AstraZeneca; 2019 [cited 2020 Dec 5]. Available from: https://www.medicines.org.uk/emc/ product/2465. link1

[25] Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 2016;62(11):1380–9. link1

[26] Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime– avibactam versus meropenem in nosocomial pneumonia, including ventilatorassociated pneumonia (REPROVE): a randomised, double-blind, phase 3 noninferiority trial. Lancet Infect Dis 2018;18(3):285–95. link1

[27] Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, et al. In vitro selection of ceftazidime–avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015;59(9):5324–30. link1

[28] García J, Nastro M, Cejas D, Santana G, Mancino MB, Hidalgo M, et al. Emergence of ceftazidime/avibactam resistance in KPC-8-producing Klebsiella pneumoniae in South America. Clin Microbiol Infect 2020;26(9):1264–5. link1

[29] Oueslati S, Iorga BI, Tlili L, Exilie C, Zavala A, Dortet L, et al. Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. J Antimicrob Chemother 2019;74(8):2239–46. link1

[30] Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. Mutations in blaKPC-3 that confer ceftazidime–avibactam resistance encode novel KPC-3 variants that function as extended-spectrum b-lactamases. Antimicrob Agents Chemother 2017;61(5):e02534–16. link1

[31] Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 2018;73 (6):1525–9. link1

[32] Göttig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S, et al. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother 2019;74(11):3211–6. link1

[33] Mueller L, Masseron A, Prod’Hom G, Galperine T, Greub G, Poirel L, et al. Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime–avibactam and exhibiting reduced carbapenemase activity. Antimicrob Agents Chemother 2019;63(12): e01111–9. link1

[34] Poirel L, Vuillemin X, Juhas M, Masseron A, Bechtel-Grosch U, Tiziani S, et al. KPC-50 confers resistance to ceftazidime–avibactam associated with reduced carbapenemase activity. Antimicrob Agents Chemother 2020;64(8): e00321–20. link1

[35] Bianco G, Boattini M, Iannaccone M, Cavallo R, Costa C. Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay. J Antimicrob Chemother 2020;75(10):3075–6. link1

[36] Niu S, Chavda KD, Wei J, Zou C, Marshall SH, Dhawan P, et al. A ceftazidime– avibactam-resistant and carbapenem-susceptible Klebsiella pneumoniae strain harboring blaKPC-14 isolated in New York City. mSphere 2020;5(4):e00775–20. link1

[37] Athans V, Neuner EA, Hassouna H, Richter SS, Keller G, Castanheira M, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime–avibactamresistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother 2019;63(1):e01551–18. link1

[38] Galani I, Karaiskos I, Angelidis E, Papoutsaki V, Galani L, Souli M, et al. Emergence of ceftazidime–avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Eur J Clin Microbiol Infect Dis 2021;40:219–24.

[39] Both A, Büttner H, Huang J, Perbandt M, Belmar Campos C, Christner M, et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother 2017;72(9):2483–8. link1

[40] Fraile-Ribot PA, Mulet X, Cabot G, Barrio-Tofiño ED, Juan C, Pérez JL, et al. In vivo emergence of resistance to novel cephalosporin-b-lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 blactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017;61(9):e01117–17. link1

[41] Galani I, Karaiskos I, Souli M, Papoutsaki V, Galani L, Gkoufa A, et al. Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime– avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Euro Surveill 2020;25(3):2000028. link1

[42] Voulgari E, Kotsakis SD, Giannopoulou P, Perivolioti E, Tzouvelekis LS, Miriagou V. Detection in two hospitals of transferable ceftazidime– avibactam resistance in Klebsiella pneumoniae due to a novel VEB blactamase variant with a Lys234Arg substitution, Greece, 2019. Euro Surveill 2020;25(2):1900766. link1

[43] Humphries RM, Hemarajata P. Resistance to ceftazidime–avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother 2017;61(6):e00537–17. link1

[44] Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, et al. Resistance to ceftazidime–avibactam is due to transposition of KPC in a porindeficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother 2017;61(10):e00989–17. link1

[45] Levitt PS, Papp-Wallace KM, Taracila MA, Hujer AM, Winkler ML, Smith KM, et al. Exploring the role of a conserved class A residue in the X-loop of KPC-2 b-lactamase: a mechanism for ceftazidime hydrolysis. J Biol Chem 2012;287 (38):31783–93. link1

[46] Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV blactamases with single amino acid substitutions in the X-loop. J Antimicrob Chemother 2015;70(8):2279–86. link1

[47] Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, et al. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime–avibactam: unique antibioticresistant phenotypes emerge from b-lactamase protein engineering. mBio 2017;8(5):e00528–17. link1

[48] Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016;63(12):1615–8. link1

[49] Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. In vitro selection of meropenem resistance among ceftazidime–avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 2017;61(5):e00079–17. link1

[50] Bush K, Bradford PA. Interplay between b-lactamases and new b-lactamase inhibitors. Nat Rev Microbiol 2019;17(5):295–306. link1

[51] Compain F, Dorchène D, Arthur M. Combination of amino acid substitutions leading to CTX-M-15-mediated resistance to the ceftazidime–avibactam combination. Antimicrob Agents Chemother 2018;62(9):e00357–18. link1

[52] Livermore DM, Mushtaq S, Doumith M, Jamrozy D, Nichols WW, Woodford N. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae. J Antimicrob Chemother 2018;73(12):3336–45. link1

[53] Lahiri SD, Alm RA. Identification of novel VEB b-lactamase enzymes and their impact on avibactam inhibition. Antimicrob Agents Chemother 2016;60 (5):3183–6. link1

[54] Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, et al. Multidrugresistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam. Infect Drug Resist 2018;11:1499–510. link1

[55] Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, et al. Selection and molecular characterization of ceftazidime/avibactamresistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 2015;70(6):1650–8. link1

[56] Compain F, Debray A, Adjadj P, Dorchêne D, Arthur M. Ceftazidime–avibactam resistance mediated by the N346Y substitution in various AmpC b-lactamases. Antimicrob Agents Chemother 2020;64(6):e02311–19. link1

[57] Karaiskos I, Galani I, Souli M, Giamarellou H. Novel b-lactam-b-lactamase inhibitor combinations: expectations for the treatment of carbapenemresistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol 2019;15(2):133–49. link1

[58] Fröhlich C, Sørum V, Thomassen AM, Johnsen PJ, Leiros HKS, Samuelsen Ø. OXA-48-mediated ceftazidime–avibactam resistance is associated with evolutionary trade-offs. mSphere 2019;4(2):e00024–19. link1

[59] Castanheira M, Mendes RE, Sader HS. Low frequency of ceftazidime–avibactam resistance among Enterobacteriaceae isolates carrying blaKPC collected in U.S. hospitals from 2012 to 2015. Antimicrob Agents Chemother 2017;61(3): e02369–16. link1

[60] Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM, Hurless KN, et al. Unexpected challenges in treating multidrug-resistant Gramnegative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob–Agents Chemother 2015;59 (2):1020–9. link1

[61] Shen Z, Ding B, Ye M, Wang P, Bi Y, Wu S, et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 2017;72(7):1930–6. link1

[62] Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F. Loss of activity of ceftazidime–avibactam due to MexAB–OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. Int J Antimicrob Agents 2018;52(5):697–701. link1

[63] Nichols WW, de Jonge BLM, Kazmierczak KM, Karlowsky JA, Sahm DF. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime–avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 2016;60(8):4743–9. link1

[64] Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, et al. High rates of nonsusceptibility to ceftazidime–avibactam and identification of New Delhi metallo-b-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. Clin Infect Dis 2016;63(7):954–8. link1

[65] Mojica MF, Bonomo RA, Fast W. B1-metallo-b-lactamases: where do we stand? Curr Drug Targets 2016;17(9):1029–50. link1

[66] Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-b-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18(2):306–25. link1

[67] Stone GG, Bradford PA, Tawadrous M, Taylor D, Cadatal MJ, Chen Z, et al. In vitro activity of ceftazidime–avibactam against isolates from respiratory and blood specimens from patients with nosocomial pneumonia, including ventilator-associated pneumonia, in a phase 3 clinical trial. Antimicrob Agents Chemother 2020;64(5):e02356–19. link1

[68] Ramalheira E, Stone GG. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012–2016. J Glob Antimicrob Resist 2019;19:106–15. link1

[69] Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime–avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012 to 2015. Antimicrob Agents Chemother 2019;63(4):e01814–18. link1

[70] Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, et al. China Antimicrobial Surveillance Network (CHINET) Study Group. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime–avibactam and ceftolozane–tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019;63(4): e02431-18. link1

[71] Nolan PJ, Jain R, Cohen L, Finklea JD, Smith TT. In vitro activity of ceftolozane– tazobactam and ceftazidime–avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Diagn Microbiol Infect Dis 2020;99(2):115204. link1

[72] Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plésiat P, et al. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Antimicrob Chemother 2015;70(5):1596–8. link1

[73] Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X, et al. Emergence of ceftazidime/ avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect 2020;26(1):124.e1-4.

[74] Li D, Liao W, Huang HH, Du FL, Wei DD, Mei YF, et al. Emergence of hypervirulent ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Resist 2020;13:2673–80. link1

[75] Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou ED, et al. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J Antimicrob Chemother 2019;74(7):2051–4. link1

[76] Manning N, Balabanian G, Rose M, Landman D, Quale J. Activity of ceftazidime–avibactam against clinical isolates of Klebsiella pneumoniae, including KPC–carrying isolates, endemic to New York City. Microb Drug Resist 2018;24(1):35–9. link1

[77] Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PRS, et al. Ceftazidime-avibactam: a novel cephalosporin/b-lactamase inhibitor combination. Drugs 2013;73(2):159–77. link1

[78] Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. Antimicrobial activity of ceftazidime–avibactam against Gram-negative organisms collected from U. S. medical centers in 2012. Antimicrob Agents Chemother 2014;58 (3):1684–92. link1

[79] Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new b-lactamases from Gram-negative bacteria. Annu Rev Microbiol 2011;65(1):455–78. link1

[80] Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. In vitro susceptibility of characterized b-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 2015;59(3):1789–93. link1